BASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical Co., Ltd. ("Qilu"). The original agreement, negotiated and implemented with CEND Therapeutics and assumed by Lisata as part of its acquisition of CEND Therapeutics in 2022, granted Qilu exclusive rights to develop and commercialize certepetide, Lisata's proprietary iRGD cyclic peptide product

Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent closing price of Lisata stock BASKING RIDGE, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a binding term sheet to be acquired by Kuva Labs, Inc. ("Kuva"), a privately-held company. Pursuant to the terms and conditions of the term

Data rich period continues to support certepetide's broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug Conjugate Technology Platform Strategic Alliance formed with GATC Health to exploit their Multiomics Advanced Technology™ artificial intelligence drug discovery platform Cash runway extended into the first quarter of 2027 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapi

BASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced it is the recipient of "Overall BioPharma Solution of the Year" in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe. This marks the second consecutive year Lisata has been honored with a BioTech Brea

BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata's licensing partner, Catalent, Inc. ("Catalent"), at the 16th Annual World ADC San Diego Conference, held November 3-6, 2025. Catalent's presentation included data demonstrating the positive impact of incorporating Lisata's proprietary iRGD cyclic peptide product candidate, certepetide, and its analogs as a payload in Catalent's SMARTag® antibody-drug conjugat

BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. To join the live conference call, please refer to the dial-in information provided below. Conference Call Dial-in information: Participant Toll-Free dial: (800) 715-9871Participant Toll/Int'l dial:

Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent's preclinical study results provide proof-of-concept support for leveraging certepetide-related biology through its use as an ADC payload BASKING RIDGE, N.J. and TAMPA, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatme

Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions BASKING RIDGE, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced encouraging preliminary data from the pancreatic ductal adenocarcinoma ("PDAC") cohort of the Phase 1/2a CENDIFOX trial (NCT05121038). The investigator-initiated trial, led by Anup Kasi, M.D., M.P.H., at The University of Kansas ("KU") Cancer Cente

BASKING RIDGE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will provide a corporate overview in a pre-recorded, on-demand presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held in New York City from September 8-10, 2025. The on-demand recording of Dr. Mazzo's presentation will be available starting Friday, September 5, 2025 at 7:00 a.m. East

Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the second quarter ended June 30, 2025. "We continued to advance our clinical development portfolio and partnering initiatives during the second quarter of 2025," st

4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

Expanded alliance combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug development Lisata to lead development efforts to advance GATC's AI-discovered therapeutic for opioid use disorder into human clinical trials early in 2026 BASKING RIDGE, N.J. and IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and GATC Health Corp. ("GATC"), a leading tech-bio company leve

BASKING RIDGE, N.J. and HOUSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Kuva Labs, a wholly owned subsidiary of Mi2 Holdings, LLC ("Kuva"), are pleased to announce a global collaboration and license agreement. Under the terms of this agreement Kuva gains access to Lisata's iRGD cyclic peptide product candidate, certepetide, as a targeting and enhanced delivery agent to be used with Kuva's NanoMark™ platform technology. This combination creates a new class of advanced magnetic resonance (MR) imaging

BASKING RIDGE, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for the treatment of endometriosis. Bevacizumab has previously demonstrated efficacy in treating endometriosis; however, the required dosage levels are associated with systemic side effects, limiting

BASKING RIDGE, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that Erkki Ruoslahti, M.D., Ph.D., has decided to retire from its Board of Directors effective today, July 11, 2023. Dr. Ruoslahti will remain associated with the Company, however, in a scientific advisory position. Dr. Ruoslahti cites the arduous requirements of international travel (he currently resides in Sweden) as well as his confidence in both the progress made with the Company's lead asset, LSTA1, and the

Data rich period continues to support certepetide's broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug Conjugate Technology Platform Strategic Alliance formed with GATC Health to exploit their Multiomics Advanced Technology™ artificial intelligence drug discovery platform Cash runway extended into the first quarter of 2027 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapi

BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. To join the live conference call, please refer to the dial-in information provided below. Conference Call Dial-in information: Participant Toll-Free dial: (800) 715-9871Participant Toll/Int'l dial:

Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the second quarter ended June 30, 2025. "We continued to advance our clinical development portfolio and partnering initiatives during the second quarter of 2025," st

BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details wi

BASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with di

BASKING RIDGE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the twelve months ended December 31, 2024, on Thursday, February 27, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call de

Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the third quarter ended September 30, 2024. "We are pleased to share the progress made in the third quarter of 2024, highlighted by the advancement of our robust development portfolio centered ar

BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To

Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024 Available cash projected to fund current operations into early 2026 and all active studies through to data Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the second quarter ended June 30, 2024. "The second quarter generated strong momentum for Lisa

BASKING RIDGE, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results the second quarter ended June 30, 2024, on Monday, August 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with di